• Something wrong with this record ?

Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic

A. Obr, K. Benesova, A. Janikova, H. Mocikova, D. Belada, A. Hruskova, P. Vockova, D. Salek, A. Sykorova, T. Furst, D. Malarikova, T. Papajik, M. Trneny, P. Klener

. 2023 ; 102 (1) : 107-115. [pub] 20221111

Language English Country Germany

Document type Multicenter Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc23004779

Ibrutinib revolutionized therapy for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Real-world data on the outcome of unselected patients are still limited. We analyzed 77 R/R MCL patients receiving ibrutinib with at least one prior systemic anti-lymphoma therapy. After a median follow-up of 14.0 months, 56 patients relapsed/progressed, and 45 died. The overall response rate was 66%, with 31% of complete metabolic remissions on PET/CT. The median progression-free and overall survival (OS) rates were 10.3 and 23.1 months, respectively. The median OS from ibrutinib failure was 3.7 months. High proliferation rate by Ki67 (≥ 30%) and two or more previous therapy lines both negatively correlated with outcome (HR = 2.2, p = 0.04, and HR = 2.06, p = 0.08, respectively). Female gender borderline correlated with better outcome (HR = 0.53, p = 0.08). In multivariate analysis, Ki67 and response to ibrutinib both correlated with OS (p < 0.05). Importantly, ibrutinib appeared to better control nodal and extranodal lymphoma than bone marrow (BM) involvement. From 20 patients with detectable BM infiltration (before ibrutinib initiation) achieving complete (n = 13) or partial (n = 7) metabolic remission, none achieved remission in BM. We confirmed good efficacy of ibrutinib in unselected heavily pre-treated MCL patients. Our findings support the use of a combination of ibrutinib and rituximab in patients with BM involvement.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004779
003      
CZ-PrNML
005      
20230425171721.0
007      
ta
008      
230418s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-022-05023-2 $2 doi
035    __
$a (PubMed)36369497
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Obr, Ales $u Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic $1 https://orcid.org/0000000267583074 $7 xx0096975
245    10
$a Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic / $c A. Obr, K. Benesova, A. Janikova, H. Mocikova, D. Belada, A. Hruskova, P. Vockova, D. Salek, A. Sykorova, T. Furst, D. Malarikova, T. Papajik, M. Trneny, P. Klener
520    9_
$a Ibrutinib revolutionized therapy for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Real-world data on the outcome of unselected patients are still limited. We analyzed 77 R/R MCL patients receiving ibrutinib with at least one prior systemic anti-lymphoma therapy. After a median follow-up of 14.0 months, 56 patients relapsed/progressed, and 45 died. The overall response rate was 66%, with 31% of complete metabolic remissions on PET/CT. The median progression-free and overall survival (OS) rates were 10.3 and 23.1 months, respectively. The median OS from ibrutinib failure was 3.7 months. High proliferation rate by Ki67 (≥ 30%) and two or more previous therapy lines both negatively correlated with outcome (HR = 2.2, p = 0.04, and HR = 2.06, p = 0.08, respectively). Female gender borderline correlated with better outcome (HR = 0.53, p = 0.08). In multivariate analysis, Ki67 and response to ibrutinib both correlated with OS (p < 0.05). Importantly, ibrutinib appeared to better control nodal and extranodal lymphoma than bone marrow (BM) involvement. From 20 patients with detectable BM infiltration (before ibrutinib initiation) achieving complete (n = 13) or partial (n = 7) metabolic remission, none achieved remission in BM. We confirmed good efficacy of ibrutinib in unselected heavily pre-treated MCL patients. Our findings support the use of a combination of ibrutinib and rituximab in patients with BM involvement.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a lymfom z plášťových buněk $x patologie $7 D020522
650    _2
$a antigen Ki-67 $7 D019394
650    _2
$a PET/CT $7 D000072078
651    _2
$a Česká republika $7 D018153
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
700    1_
$a Benesova, Katerina $u First Department of Internal Medicine-Department of Haematology, University General Hospital and First Faculty of Medicine, Charles University, U Nemocnice 499/2, Prague, 12808, Czech Republic
700    1_
$a Janikova, Andrea $u Department of Haematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Mocikova, Heidi $u Department of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Belada, David $u 4th Department of Internal Medicine-Haematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
700    1_
$a Hruskova, Andrea $u Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
700    1_
$a Vockova, Petra $u First Department of Internal Medicine-Department of Haematology, University General Hospital and First Faculty of Medicine, Charles University, U Nemocnice 499/2, Prague, 12808, Czech Republic
700    1_
$a Salek, David $u Department of Haematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Sykorova, Alice $u 4th Department of Internal Medicine-Haematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
700    1_
$a Furst, Tomas $u Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science, Palacky University, Olomouc, Czech Republic
700    1_
$a Malarikova, Diana $u First Department of Internal Medicine-Department of Haematology, University General Hospital and First Faculty of Medicine, Charles University, U Nemocnice 499/2, Prague, 12808, Czech Republic
700    1_
$a Papajik, Tomas $u Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
700    1_
$a Trneny, Marek $u First Department of Internal Medicine-Department of Haematology, University General Hospital and First Faculty of Medicine, Charles University, U Nemocnice 499/2, Prague, 12808, Czech Republic
700    1_
$a Klener, Pavel $u First Department of Internal Medicine-Department of Haematology, University General Hospital and First Faculty of Medicine, Charles University, U Nemocnice 499/2, Prague, 12808, Czech Republic. pavel.klener2@vfn.cz $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. pavel.klener2@vfn.cz
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 102, č. 1 (2023), s. 107-115
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36369497 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171717 $b ABA008
999    __
$a ok $b bmc $g 1925083 $s 1190988
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 102 $c 1 $d 107-115 $e 20221111 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options